Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00377-6/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--_HU5DSL70ZmnN8lTJiwmnmUqO3XqkM68zseHyd1SRqILJnmSKBez_rx4M7W4qzbmr6Em_4yZVE2WwhNsbCeW14KoUWg&_hsmi=356487988&utm_content=356303552&utm_source=hs_email